Review: taking Amitiza and Dolophine hydrochloride together


Summary

Drug interactions are reported among people who take Amitiza and Dolophine hydrochloride together. This review analyzes the effectiveness and drug interactions between Amitiza and Dolophine hydrochloride. It is created by eHealthMe based on reports of 31 people who take the same drugs from FDA and social media, and is updated regularly.

You are not alone

Join a support group for people who take Amitiza and Dolophine hydrochloride >>>

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Amitiza

Amitiza has active ingredients of lubiprostone. It is often used in constipation. (latest outcomes from Amitiza 2,379 users)

Dolophine Hydrochloride

Dolophine hydrochloride has active ingredients of methadone hydrochloride. It is often used in rheumatoid arthritis. (latest outcomes from Dolophine hydrochloride 26 users)

On Aug, 25, 2016

31 people who take Amitiza, Dolophine Hydrochloride are studied.


Number of reports submitted per year:

Amitiza and Dolophine hydrochloride drug interactions.

Drug effectiveness over time:

Amitiza:
  • < 1 month: 0.0% - (0 of 0 people)
  • 1 - 6 months: 0.0% - (0 of 0 people)
  • 6 - 12 months: 0.0% - (0 of 0 people)
  • 1 - 2 years: 0.0% - (0 of 0 people)
  • 2 - 5 years: 0.0% - (0 of 2 people)
  • 5 - 10 years: 0.0% - (0 of 0 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 0.0% - (0 of 0 people)
Dolophine Hydrochloride:
  • < 1 month: 0.0% - (0 of 0 people)
  • 1 - 6 months: 0.0% - (0 of 0 people)
  • 6 - 12 months: 0.0% - (0 of 0 people)
  • 1 - 2 years: 0.0% - (0 of 0 people)
  • 2 - 5 years: 0.0% - (0 of 1 people)
  • 5 - 10 years: 0.0% - (0 of 1 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 0.0% - (0 of 0 people)

Drug effectiveness by gender:

Amitiza:
  • female: 0.0% - (0 of 0 people)
  • male: 0.0% - (0 of 2 people)
Dolophine Hydrochloride:
  • female: 0.0% - (0 of 0 people)
  • male: 0.0% - (0 of 2 people)

Drug effectiveness by age:

Amitiza:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 0 people)
  • 30-39: 0.0% - (0 of 0 people)
  • 40-49: 0.0% - (0 of 0 people)
  • 50-59: 0.0% - (0 of 1 people)
  • 60+: 0.0% - (0 of 1 people)
Dolophine Hydrochloride:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 0 people)
  • 30-39: 0.0% - (0 of 0 people)
  • 40-49: 0.0% - (0 of 0 people)
  • 50-59: 0.0% - (0 of 1 people)
  • 60+: 0.0% - (0 of 1 people)

Most common drug interactions over time *:

< 1 month:
  • chills
  • lacrimation increased
  • lung neoplasm malignant
  • nausea
  • yawning
  • blood pressure decreased
  • diarrhoea
  • pyrexia
  • affect lability
1 - 6 months:
  • acute myocardial infarction
  • confusional state
  • drug administration error
  • haematocrit decreased
  • haemoglobin decreased
  • obstruction gastric
  • pneumonia aspiration
  • renal failure acute
  • white blood cell count decreased
not specified:
  • pain
  • anxiety
  • osteomyelitis
  • constipation
  • dyspnoea
  • anaemia
  • chronic obstructive pulmonary disease
  • malaise
  • nausea
  • vomiting

Most common drug interactions by gender *:

female:
  • pain
  • anxiety
  • osteomyelitis
  • constipation
  • dyspnoea
  • nausea
  • anaemia
  • chronic obstructive pulmonary disease
  • malaise
  • actinomycosis
male:
  • pneumonia aspiration
  • acute myocardial infarction
  • blood pressure decreased
  • confusional state
  • diarrhoea
  • drug administration error
  • haematocrit decreased
  • haemoglobin decreased
  • lung neoplasm malignant
  • major depression

Most common drug interactions by age *:

30-39:
  • multiple sclerosis relapse
40-49:
  • constipation
  • dyspnoea
  • actinomycosis
  • anaemia
  • anxiety
  • bone disorder
  • bone pain
  • bronchitis
  • candidiasis
  • cerebral atrophy
50-59:
  • injection site pain
  • anxiety
  • asphyxia
  • decubitus ulcer
  • osteomyelitis
  • urinary tract infection
  • blood glucose increased
  • unresponsive to stimuli
  • aphasia
  • asthenia
60+:
  • disseminated intravascular coagulation
  • affect lability
  • cardio-respiratory arrest
  • chills
  • lacrimation increased
  • nausea
  • post procedural haemorrhage
  • urethral polyp
  • yawning
  • anaemia

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you take Amitiza and Dolophine hydrochloride?

You may be interested in these reviews

More reviews for: Amitiza, Dolophine hydrochloride

On eHealthMe, Amitiza (lubiprostone) is often used to treat constipation. Dolophine hydrochloride (methadone hydrochloride) is often used to treat rheumatoid arthritis. Find out below the conditions the drugs are used for and how effective they are.

What is the drug used for and how effecitve is it:


NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.